| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small sample | 100.0% (4/4) | 50.0% (2/4) | +0.8% | +0.7% | -1.3% |
| 20D | 4Small sample | 100.0% (4/4) | 50.0% (2/4) | -0.5% | +0.7% | -3.7% |
| 60D | 4Small sample | 100.0% (4/4) | 0.0% (0/4) | -7.5% | -9.1% | -19.1% |
| 120D | 4Small sample | 100.0% (4/4) | 0.0% (0/4) | -21.3% | -22.4% | -38.1% |
COMPANY RESEARCH
Hikma Pharmaceuticals PLC
HIK.L · United Kingdom · Healthcare · Drug Manufacturers—Specialty & Generic
INSIDER SIGNAL
Insider activity score：67.8 / 100
6 insiders · 8 purchase events · €471k net purchases
Europe #102 · United Kingdom #31
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+35.0 / 35
How many distinct insiders bought in the cluster
Purchase size+21.2 / 25
Purchase value relative to company size and liquidity
Role+20.0 / 20
The seniority and relevance of participating insiders
Recency+1.7 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Purchase activity is becoming less recent
- ✓ Broad buyer cluster · 4+ distinct filers
- ✓ Strong insider role · ceo/chair involved
The role contribution uses the inverted role input of the current European model.
Buying concentration
50%
Largest buyer：Victoria Hull · 199k GBP
Gross qualified purchase transaction-line value：397k GBP
The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Susan Ringdal | 15.97 GBP | Sep 21, 2026 |
| Julie Hill | 15.97 GBP | Sep 21, 2026 |
| Victoria Hull | 13.76 GBP | Apr 27, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 4 distinct reported filers
- Peak time window
- 2026-04-27 to 2026-05-05
- Current breadth input
- 1.000 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
Susan Ringdal · 27k GBP · Price 15.97 GBP · Sep 21, 2026 - 🟢 Eligible purchase
Julie Hill · 3k GBP · Price 15.97 GBP · Sep 21, 2026 - 🟢 PDMR purchase
Victoria Hull · 199k GBP · Price 13.76 GBP · Apr 27, 2026 - 🟡 5 remaining qualified transaction line(s) across 5 disclosure(s)
- 🔴 20 other transaction line(s) are not counted as discretionary-buying evidence; 6 have zero price
Insider vs stock price
4 purchase day(s), 8 purchase line(s) in the 180-day window.
Daily close (GBp)Day with an insider purchaseTwo or more insiders the same day
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-04-28 | 1 | 1,178 +17.8% | 1,035 +3.5% | +144 +14.4 pts |
| 2026-05-06 | 3 | 1,151 +15.1% | 1,028 +2.8% | +123 +12.3 pts |
| 2026-08-11 | 1 | 1,005 +0.5% | 975 −2.5% | +30 +3.0 pts |
| 2026-09-22 | 3 | 1,025 +2.5% | 988 −1.2% | +36 +3.6 pts |
4 of 4 disclosure day(s) ended ahead of the median peer stock.
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (454 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
4 insiders bought within 9 days, 27 Apr to 5 May: 3 Role not classified, 1 CEO / chair. 2 of them bought again later. 2 more bought afterwards. The share closed at 1,386.00 on the first of those days and at 1,646.00 most recently (+18.8%). That week 203 companies across Europe disclosed insider purchases, an ordinary week (8 of the last 26).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount.
▮Purple band: several insiders bought within 15 days
The band marks the stretch with the most different buyers: at most 15 days long and at least two people. Here it is 27 Apr – 5 May, with 4 insiders. Only the strongest stretch is marked. Several people deciding the same thing is harder to explain by one person's private reasons, but insiders often buy together just after a closed period ends, so compare it with the grey weekly bars.
Blue line: this share's price, +22.1% over these six months
The closing price of each day, from 1,348.00 on 2026-04-21 to 1,646.00 on 2026-10-07. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, +2.3%
Taken from the 491 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share +22.1%, the typical one +2.3%, 19.8 points ahead. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases. The purple bar is the week of the band above: 203 companies, number 8 of the last 26 weeks. If that week was a peak anyway, buying together is less special than it looks.
This company: insiders buying per month, last 12 months
3Nov
1Dec
Jan
Feb
1Mar
1Apr
3May
Jun
Jul
1Aug
3Sep
Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| Victoria Hull | CEO / chair | 1 | — | 198.9k GBP | 2026-04-27 | +18.8% | fewer than 5 completed |
| Tobias Hestler | Board member | 1 | — | 123.6k GBP | 2026-08-10 | −0.2% | fewer than 5 completed |
| Hussein Arkhagha | Role not classified | 1 | — | 5.7k GBP | 2026-05-05 | +16.7% | fewer than 5 completed |
| Julie Hill | Role not classified | 2 | — | 6.0k GBP | 2026-05-05 | +16.7% | fewer than 5 completed |
| Susan Ringdal | Role not classified | 2 | — | 59.8k GBP | 2026-05-05 | +16.7% | fewer than 5 completed |
| Sam Park | Role not classified | 1 | — | 3.3k GBP | 2026-09-21 | +2.2% | fewer than 5 completed |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 1.000 | 35.0 |
| Qualified-buy size | 25% | 0.847 | 21.2 |
| Role informativeness (inverted) | 20% | 0.000 | 0.0 |
| Recency | 10% | 0.165 | 1.7 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13, neither column has changed. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
Independent evidence does not object: the purchases themselves carry bull lines (senior executive buying); share price and trading, short sellers, company results, company actions were checked and none crosses a bear threshold.
- The insider purchases themselvesBullsenior executive buying Bearplan, dividend or pay wording7 checked, under the threshold · 2 missing
- Share price and trading2 checked, under the threshold
- Short sellers1 checked, under the threshold
- Company results1 checked, under the threshold · 1 missing
- Company actions1 checked, under the threshold
Bull case · the buying is informative
- The buyers include the CEO or chair, who sees more of the business than most filers. This site's score gives little or no credit for that: in its backtests purchases by senior executives did no better than other insiders' purchases.Record: after 8,797 earlier disclosures like this, the median 60-session excess return was −3.1%, within 1 percentage point of all comparable disclosures (−3.2%).
Bear case · discount it
- 6 of 8 purchase lines are worded as dividend reinvestment or scrip, for example “Acquisition of Ordinary Shares through participation in a DRIP”. Purchases of that kind follow a schedule or an entitlement, not a decision made now.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin 11%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 12, 2 close to it
- EitherNet purchases equal 0.01% of the company's market value. Bull from 0.10%, bear below 0.01%. close to the threshold
- BearPublished net short positions total 1.70% of the share capital. Counted for the bear side from 2%. On 2026-10-02 it was 1.29%: up 0.41 points since. close to the threshold
- BullAt most 1 insider bought within any 15 days. Counted for the bull side from 3.
- Either6 insiders bought in the last 180 days and 4 in the 180 days before. Bull when the number at least doubles and rises by two; bear when at least two bought before and no more buy now.
- BearThe largest buyer accounts for 50% of the value bought. Counted for the bear side from 80%.
- Bear0 of 6 buyers filed as a person closely associated with a manager. Counted for the bear side from half.
- BearNo insider sale is recorded in the same 180 days.
- EitherThe latest purchase is 26 days old. Bull up to 14 days, bear from 90.
- BearThe share price changed +24% over six months (three months +1.9%, one month +3.1%) and stands 12% below its 52-week high. Counted for the bear side from a fall of 20%.
- BearOver three months the share price changed +1.9% and the median of 271 Healthcare companies changed −6.3%: ahead by 8 points. Counted for the bear side from 20 points behind.
- BullThe company announced no transaction in its own shares in the last 30 days.
- BearProfit margin on the latest captured figures is 11%. Counted for the bear side when negative.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
67.8 / 100
Latest recorded score
↑ +0.9 ptsversus the comparable snapshot on 2026-09-14 (34 calendar days apart)
- Recorded snapshots
- 35
- First snapshot
- 2026-08-26
Only scores captured when the scoring run completed are compared. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Decomposition across the five score factors between comparable snapshots; historical scores are not recalculated.
- Purchase size+0.2 pts
- Recency+0.8 pts
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 65.8
- 67.4
- 72.3
- 69.5
- 67.8
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-08-26 | 65.8 |
| 2026-08-27 | 65.8 |
| 2026-08-28 | 69.2 |
| 2026-08-31 | 68.6 |
| 2026-09-01 | 68.5 |
| 2026-09-02 | 68.3 |
| 2026-09-03 | 68.2 |
| 2026-09-04 | 68.1 |
| 2026-09-07 | 67.4 |
| 2026-09-08 | 67.3 |
| 2026-09-09 | 67.2 |
| 2026-09-10 | 67.2 |
| 2026-09-11 | 67.1 |
| 2026-09-14 | 66.9 |
| 2026-09-23 | 74.8 |
| 2026-09-24 | 74.3 |
| 2026-09-25 | 73.7 |
| 2026-09-28 | 72.3 |
| 2026-09-29 | 71.9 |
| 2026-09-30 | 71.5 |
| 2026-10-01 | 71.2 |
| 2026-10-02 | 70.8 |
| 2026-10-03 | 70.8 |
| 2026-10-04 | 70.8 |
| 2026-10-05 | 70.0 |
| 2026-10-06 | 69.7 |
| 2026-10-07 | 69.5 |
| 2026-10-08 | 69.2 |
| 2026-10-09 | 69.0 |
| 2026-10-12 | 68.5 |
| 2026-10-13 | 68.3 |
| 2026-10-14 | 68.2 |
| 2026-10-15 | 68.1 |
| 2026-10-16 | 67.9 |
| 2026-10-18 | 67.8 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − FTSE 100 return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small sample | 100.0% (4/4) | 100.0% (4/4) | +1.3% | +1.6% | +0.6% |
| 20D | 3Small sample | 100.0% (3/3) | 100.0% (3/3) | +2.9% | +4.0% | +1.5% |
| 60D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -10.5% | -5.2% | -12.3% |
| 120D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -30.4% | -30.4% | -34.9% |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 4Small sample | 100.0% (4/4) | 100.0% (4/4) | +1.3% | +1.6% | +0.6% |
| 20D | 3Small sample | 100.0% (3/3) | 100.0% (3/3) | +2.9% | +4.0% | +1.5% |
| 60D | 3Small sample | 100.0% (3/3) | 33.3% (1/3) | -10.5% | -5.2% | -12.3% |
| 120D | 2Small sample | 100.0% (2/2) | 0.0% (0/2) | -30.4% | -30.4% | -34.9% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 29.7%
- Beta
- 0.66
- Avg daily volume
- £15.3M
VALUATION
- Market cap
- £3.3B
- P/E
- 12.0×
FUNDAMENTALS
- Profit margin
- 11.3%
- ROE
- 15.4%
- Industry
- Drug Manufacturers - Specialty & Generic
Prices to 07 Oct 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 07 Oct 2026: Market cap, P/E, Profit margin, ROE, Beta, Industry. It does not affect the insider score or rank.
Disclosed net short positions
- Aggregate net short
- 1.70%
- Latest position date
- 14 Oct 2026
The FCA publishes one aggregate figure per issuer, the sum of all positions notified to it, and does not name the holders. Source: FCA · read 18 Oct 2026
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
The latest close in the price history is more than a week old.
Buying size vs market trading
Market history is too old for this snapshot; ratios are withheld.
Market-data coverage: 507 verified sessions · Latest session: 2026-10-07 · Ratio status: Unavailable
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
- Insider filing announcement · published 2026-09-22 · trade date 2026-09-21
- Insider filing announcement · published 2026-08-24 · trade date 2026-08-21
- Insider filing announcement · published 2026-08-11 · trade date 2026-08-10
Unfold all 14 filings
- Insider filing announcement · published 2026-09-22 · trade date 2026-09-21
- Insider filing announcement · published 2026-08-24 · trade date 2026-08-21
- Insider filing announcement · published 2026-08-11 · trade date 2026-08-10
- Insider filing announcement · published 2026-06-02 · trade date 2026-06-01
- Insider filing announcement · published 2026-05-06 · trade date 2026-05-05
- Insider filing announcement · published 2026-04-28 · trade date 2026-04-27
- Insider filing announcement · published 2026-04-13 · trade date 2026-04-09
- Insider filing announcement · published 2026-04-09 · trade date 2026-04-07
- Insider filing announcement · published 2026-03-11 · trade date 2026-03-09
- Insider filing announcement · published 2025-12-19 · trade date 2025-12-19
- Insider filing announcement · published 2025-12-19 · trade date 2025-12-19
- Insider filing announcement · published 2025-12-15 · trade date 2025-12-12
- Insider filing announcement · published 2025-11-11 · trade date 2025-11-07
- Insider filing announcement · published 2025-11-07 · trade date 2025-11-07
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
19 qualifying purchase disclosure(s) · 19 transaction line(s)
Sep 21, 2026Acquisition of Ordinary Shares through participation in a DRIP.
Susan Ringdal · PDMR
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 · 1684 shares × 15.97 GBP · —
Open filingSep 21, 2026Acquisition of Ordinary Shares through participation in a DRIP.
Julie Hill · PDMR
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 · 218 shares × 15.97 GBP · —
Open filingSep 21, 2026Acquisition of Ordinary Shares through participation in a DRIP.
Sam Park · PDMR
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 · 207 shares × 15.97 GBP · —
Open filingUnfold all 16 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | 2026-08-11 | Tobias Hestler | Non-Executive Director | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.48 GBP | GBP | 7500 | Open filing |
| 2026-05-05 | 2026-05-06 | Hussein Arkhagha | PDMR | Acquisition of Ordinary Shares through participation in a DRIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.098 GBP | GBP | 407 | Open filing |
| 2026-05-05 | 2026-05-06 | Susan Ringdal | PDMR | Acquisition of Ordinary Shares through participation in a DRIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.098 GBP | GBP | 2337 | Open filing |
| 2026-05-05 | 2026-05-06 | Julie Hill | PDMR | Acquisition of Ordinary Shares through participation in a DRIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.098 GBP | GBP | 178 | Open filing |
| 2026-04-27 | 2026-04-28 | Victoria Hull | Non-Executive Chair | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 13.76 GBP | GBP | 14455 | Open filing |
| 2026-03-09 | 2026-03-11 | Hussein Arkhagha | PDMR | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 12.00 GBP | GBP | 6200 | Open filing |
| 2025-12-19 | 2025-12-19 | Mazen Darwazah | Executive Vice Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.986 GBP | GBP | 100000 | Open filing |
| 2025-11-07 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.41 GBP | GBP | 70000 | Open filing |
| 2025-11-07 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.89 GBP | GBP | 60000 | Open filing |
| 2025-11-07 | 2025-11-07 | Victoria Hull | Senior Independent Director | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.47 GBP | GBP | 3214 | Open filing |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.05 GBP | GBP | 100000 | Open filing |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.16 GBP | GBP | 100000 | Open filing |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.92 GBP | GBP | 100000 | Open filing |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.25 GBP | GBP | 100000 | Open filing |
| 2025-11-06 | 2025-11-07 | Mazen Darwazah | Executive Vice Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.90 GBP | GBP | 115000 | Open filing |
| 2025-11-06 | 2025-11-07 | Mazen Darwazah | Executive Vice Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.07 GBP | GBP | 200000 | Open filing |
Showing 19 of 19 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 48 other transaction(s)
Aug 21, 2026Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Chief Executive Officer, who is a director and shareholder of Darhold Limited.
Said Darwazah · Chief Executive Officer
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 · 2000000 shares × 0.00 GBP · —
Open filingAug 21, 2026Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Chief Executive Officer, who is a director and shareholder of Darhold Limited.
Said Darwazah · Chief Executive Officer
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 · 2000000 shares × 0.00 GBP · —
Open filingAug 21, 2026Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman and Deputy CEO, MENA, who is a director and shareholder of Darhold Limited.
Mazen Darwazeh · Executive Vice Chairman and Deputy CEO, MENA
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 · 2000000 shares × 0.00 GBP · —
Open filingUnfold all 45 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-21 | 2026-08-24 | Mazen Darwazeh | Executive Vice Chairman and Deputy CEO, MENA | Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman and Deputy CEO, MENA, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2000000 | Open filing |
| 2026-08-21 | 2026-08-24 | Ali Al-Husry | Non-Executive Director | Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2000000 | Open filing |
| 2026-08-21 | 2026-08-24 | Ali Al-Husry | Non-Executive Director | Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2000000 | Open filing |
| 2026-06-01 | 2026-06-02 | Said Darwazah | Chief Executive Officer | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 91812 | Open filing |
| 2026-06-01 | 2026-06-02 | Said Darwazah | Chief Executive Officer | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 19761 | Open filing |
| 2026-06-01 | 2026-06-02 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 72763 | Open filing |
| 2026-06-01 | 2026-06-02 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 20650 | Open filing |
| 2026-06-01 | 2026-06-02 | Khalid Nabilsi | Deputy CEO, North America and Europe | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 51650 | Open filing |
| 2026-06-01 | 2026-06-02 | Khalid Nabilsi | Deputy CEO, North America and Europe | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 22209 | Open filing |
| 2026-06-01 | 2026-06-02 | Bassam Kanaan | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 52640 | Open filing |
| 2026-06-01 | 2026-06-02 | Bassam Kanaan | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 20982 | Open filing |
| 2026-06-01 | 2026-06-02 | Hussein Arkhagha | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 28631 | Open filing |
| 2026-06-01 | 2026-06-02 | Hussein Arkhagha | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 12406 | Open filing |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 26558 | Open filing |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 11664 | Open filing |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | All shares sold following the vesting of conditional awards under the LTIP and EIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 14.49 GBP | GBP | 26558 | Open filing |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | All shares sold following the vesting of conditional awards under the LTIP and EIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 14.49 GBP | GBP | 11664 | Open filing |
| 2026-04-09 | 2026-04-13 | Julie Hill | PDMR | Shares acquired from the vesting of conditional awards under the LTIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 8188 | Open filing |
| 2026-04-09 | 2026-04-13 | Julie Hill | PDMR | Shares sold to cover tax following the vesting of conditional awards under the LTIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 13.09 GBP | GBP | 3121 | Open filing |
| 2026-04-09 | 2026-04-13 | Sam Park | PDMR | Shares acquired from the vesting of conditional awards under the LTIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 19045 | Open filing |
| 2026-04-09 | 2026-04-13 | Sam Park | PDMR | Shares sold to cover tax following the vesting of conditional awards under the LTIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 13.09 GBP | GBP | 7259 | Open filing |
| 2026-04-07 | 2026-04-09 | Said Darwazah | Chief Executive Officer | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 158336 | Open filing |
| 2026-04-07 | 2026-04-09 | Said Darwazah | Chief Executive Officer | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 28149 | Open filing |
| 2026-04-07 | 2026-04-09 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 126364 | Open filing |
| 2026-04-07 | 2026-04-09 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 36135 | Open filing |
| 2026-04-07 | 2026-04-09 | Khalid Nabilsi | Deputy CEO, North America and Europe | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 100792 | Open filing |
| 2026-04-07 | 2026-04-09 | Hussein Arkhagha | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 59221 | Open filing |
| 2026-04-07 | 2026-04-09 | Bassam Kanaan | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 88860 | Open filing |
| 2026-04-07 | 2026-04-09 | Susan Ringdal | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 49502 | Open filing |
| 2026-04-07 | 2026-04-09 | Julie Hill | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 40043 | Open filing |
| 2026-04-07 | 2026-04-09 | Hafrun Fridriksdottir | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 87317 | Open filing |
| 2026-04-07 | 2026-04-09 | Sam Park | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 61940 | Open filing |
| 2026-04-07 | 2026-04-09 | Sam Park | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 23000 | Open filing |
| 2025-12-19 | 2025-12-19 | Said Darwazah | Executive Chairman and CEO | Release of a pledge Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | Open filing |
| 2025-12-19 | 2025-12-19 | Said Darwazah | Executive Chairman and CEO | Grant of a pledge by Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Europe Arab Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | Open filing |
| 2025-12-19 | 2025-12-19 | Mazen Darwazah | Executive Vice Chairman | Release of a pledge Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | Open filing |
| 2025-12-19 | 2025-12-19 | Mazen Darwazah | Executive Vice Chairman | Grant of a pledge by Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Europe Arab Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | Open filing |
| 2025-12-19 | 2025-12-19 | Ali Al-Husry | Non-Executive Director | Release of a pledge Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | Open filing |
| 2025-12-19 | 2025-12-19 | Ali Al-Husry | Non-Executive Director | Grant of a pledge by Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Europe Arab Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | Open filing |
| 2025-12-12 | 2025-12-15 | Said Darwazah | Executive Chairman and CEO | Release of a pledge Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | Open filing |
| 2025-12-12 | 2025-12-15 | Said Darwazah | Executive Chairman and CEO | Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of EFG International Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | Open filing |
| 2025-12-12 | 2025-12-15 | Mazen Darwazah | Executive Vice Chairman | Release of a pledge Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | Open filing |
| 2025-12-12 | 2025-12-15 | Mazen Darwazah | Executive Vice Chairman | Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of EFG International Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | Open filing |
| 2025-12-12 | 2025-12-15 | Ali Al-Husry | Non-Executive Director | Release of a pledge Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | Open filing |
| 2025-12-12 | 2025-12-15 | Ali Al-Husry | Non-Executive Director | Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of EFG International Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | Open filing |
Showing 48 of 48 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- HIK.L
- ISIN
- GB00B0LCW083
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
Company logos by Parqet